Go Pro
→ SPCX Warning - and Worst News for Stocks in 50 Years (From TradeSmith) (Ad)tc pixel Free RUA Stock Alerts

RUA Life Sciences (RUA) Competitors

RUA Life Sciences logo
GBX 18.10 +0.35 (+1.97%)
As of 06/26/2026 09:59 AM Eastern
Compare

RUA vs. IUG, NCYT, IHC, AVO, and MHC

Should you buy RUA Life Sciences stock or one of its competitors? MarketBeat compares RUA Life Sciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with RUA Life Sciences include Intelligent Ultrasound Group (IUG), Novacyt (NCYT), Inspiration Healthcare Group (IHC), Advanced Oncotherapy (AVO), and MyHealthChecked (MHC). These companies are all part of the "medical devices" industry.

How does RUA Life Sciences compare to Intelligent Ultrasound Group?

Intelligent Ultrasound Group (LON:IUG) and RUA Life Sciences (LON:RUA) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, risk, earnings, analyst recommendations, institutional ownership, profitability, valuation and dividends.

RUA Life Sciences has a net margin of -3.26% compared to Intelligent Ultrasound Group's net margin of -23.11%. RUA Life Sciences' return on equity of -2.03% beat Intelligent Ultrasound Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Intelligent Ultrasound Group-23.11% -23.58% -13.51%
RUA Life Sciences -3.26%-2.03%-17.50%

Intelligent Ultrasound Group has a beta of 0.38, suggesting that its stock price is 62% less volatile than the broader market. Comparatively, RUA Life Sciences has a beta of 0.958, suggesting that its stock price is 4% less volatile than the broader market.

Intelligent Ultrasound Group has higher revenue and earnings than RUA Life Sciences.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Intelligent Ultrasound Group£6.57M0.00-£2.27M-£0.68N/A
RUA Life Sciences£4.11M2.73-£2.66MN/AN/A

75.5% of Intelligent Ultrasound Group shares are owned by institutional investors. Comparatively, 0.1% of RUA Life Sciences shares are owned by institutional investors. 12.8% of Intelligent Ultrasound Group shares are owned by company insiders. Comparatively, 7.3% of RUA Life Sciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Intelligent Ultrasound Group's average media sentiment score of 0.00 equaled RUA Life Sciences'average media sentiment score.

Company Overall Sentiment
Intelligent Ultrasound Group Neutral
RUA Life Sciences Neutral

Summary

Intelligent Ultrasound Group beats RUA Life Sciences on 5 of the 9 factors compared between the two stocks.

How does RUA Life Sciences compare to Novacyt?

RUA Life Sciences (LON:RUA) and Novacyt (LON:NCYT) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, earnings, media sentiment, risk, dividends and valuation.

In the previous week, Novacyt had 1 more articles in the media than RUA Life Sciences. MarketBeat recorded 1 mentions for Novacyt and 0 mentions for RUA Life Sciences. RUA Life Sciences' average media sentiment score of 0.00 equaled Novacyt'saverage media sentiment score.

Company Overall Sentiment
RUA Life Sciences Neutral
Novacyt Neutral

RUA Life Sciences has higher earnings, but lower revenue than Novacyt.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
RUA Life Sciences£4.11M2.73-£2.66MN/AN/A
Novacyt£20.03M1.22-£36.80M-£32.00N/A

RUA Life Sciences has a net margin of -3.26% compared to Novacyt's net margin of -135.96%. RUA Life Sciences' return on equity of -2.03% beat Novacyt's return on equity.

Company Net Margins Return on Equity Return on Assets
RUA Life Sciences-3.26% -2.03% -17.50%
Novacyt -135.96%-121.30%-27.98%

RUA Life Sciences has a beta of 0.958, indicating that its share price is 4% less volatile than the broader market. Comparatively, Novacyt has a beta of 1.105, indicating that its share price is 11% more volatile than the broader market.

0.1% of RUA Life Sciences shares are owned by institutional investors. Comparatively, 10.7% of Novacyt shares are owned by institutional investors. 7.3% of RUA Life Sciences shares are owned by insiders. Comparatively, 0.7% of Novacyt shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

RUA Life Sciences beats Novacyt on 6 of the 11 factors compared between the two stocks.

How does RUA Life Sciences compare to Inspiration Healthcare Group?

Inspiration Healthcare Group (LON:IHC) and RUA Life Sciences (LON:RUA) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, valuation, institutional ownership, risk, dividends, earnings and analyst recommendations.

RUA Life Sciences has lower revenue, but higher earnings than Inspiration Healthcare Group.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Inspiration Healthcare Group£45.20M0.44-£12.20M-£13.65N/A
RUA Life Sciences£4.11M2.73-£2.66MN/AN/A

Inspiration Healthcare Group has a beta of 0.867, indicating that its stock price is 13% less volatile than the broader market. Comparatively, RUA Life Sciences has a beta of 0.958, indicating that its stock price is 4% less volatile than the broader market.

In the previous week, Inspiration Healthcare Group's average media sentiment score of 0.00 equaled RUA Life Sciences'average media sentiment score.

Company Overall Sentiment
Inspiration Healthcare Group Neutral
RUA Life Sciences Neutral

Inspiration Healthcare Group has a net margin of -2.19% compared to RUA Life Sciences' net margin of -3.26%. RUA Life Sciences' return on equity of -2.03% beat Inspiration Healthcare Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Inspiration Healthcare Group-2.19% -6.49% -3.47%
RUA Life Sciences -3.26%-2.03%-17.50%

7.4% of Inspiration Healthcare Group shares are held by institutional investors. Comparatively, 0.1% of RUA Life Sciences shares are held by institutional investors. 8.4% of Inspiration Healthcare Group shares are held by insiders. Comparatively, 7.3% of RUA Life Sciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Inspiration Healthcare Group beats RUA Life Sciences on 6 of the 10 factors compared between the two stocks.

How does RUA Life Sciences compare to Advanced Oncotherapy?

RUA Life Sciences (LON:RUA) and Advanced Oncotherapy (LON:AVO) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, earnings, dividends, institutional ownership, media sentiment, risk and profitability.

0.1% of RUA Life Sciences shares are owned by institutional investors. Comparatively, 17.8% of Advanced Oncotherapy shares are owned by institutional investors. 7.3% of RUA Life Sciences shares are owned by insiders. Comparatively, 47.5% of Advanced Oncotherapy shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

RUA Life Sciences has higher revenue and earnings than Advanced Oncotherapy.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
RUA Life Sciences£4.11M2.73-£2.66MN/AN/A
Advanced OncotherapyN/AN/A-£32.60M-£0.07N/A

In the previous week, RUA Life Sciences' average media sentiment score of 0.00 equaled Advanced Oncotherapy'saverage media sentiment score.

Company Overall Sentiment
RUA Life Sciences Neutral
Advanced Oncotherapy Neutral

Advanced Oncotherapy has a net margin of 0.00% compared to RUA Life Sciences' net margin of -3.26%. RUA Life Sciences' return on equity of -2.03% beat Advanced Oncotherapy's return on equity.

Company Net Margins Return on Equity Return on Assets
RUA Life Sciences-3.26% -2.03% -17.50%
Advanced Oncotherapy N/A -67.34%-11.73%

RUA Life Sciences has a beta of 0.958, suggesting that its share price is 4% less volatile than the broader market. Comparatively, Advanced Oncotherapy has a beta of 0.06, suggesting that its share price is 94% less volatile than the broader market.

Summary

RUA Life Sciences beats Advanced Oncotherapy on 5 of the 9 factors compared between the two stocks.

How does RUA Life Sciences compare to MyHealthChecked?

MyHealthChecked (LON:MHC) and RUA Life Sciences (LON:RUA) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, media sentiment, earnings, profitability, valuation, analyst recommendations, institutional ownership and risk.

MyHealthChecked has a beta of 1.37, indicating that its share price is 37% more volatile than the broader market. Comparatively, RUA Life Sciences has a beta of 0.958, indicating that its share price is 4% less volatile than the broader market.

RUA Life Sciences has a net margin of -3.26% compared to MyHealthChecked's net margin of -60.34%. RUA Life Sciences' return on equity of -2.03% beat MyHealthChecked's return on equity.

Company Net Margins Return on Equity Return on Assets
MyHealthChecked-60.34% -30.82% -8.18%
RUA Life Sciences -3.26%-2.03%-17.50%

0.7% of MyHealthChecked shares are owned by institutional investors. Comparatively, 0.1% of RUA Life Sciences shares are owned by institutional investors. 9.3% of MyHealthChecked shares are owned by company insiders. Comparatively, 7.3% of RUA Life Sciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

MyHealthChecked has higher earnings, but lower revenue than RUA Life Sciences.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MyHealthChecked£3.22M1.48-£1.04M-£3.76N/A
RUA Life Sciences£4.11M2.73-£2.66MN/AN/A

In the previous week, MyHealthChecked's average media sentiment score of 0.00 equaled RUA Life Sciences'average media sentiment score.

Company Overall Sentiment
MyHealthChecked Neutral
RUA Life Sciences Neutral

Summary

MyHealthChecked beats RUA Life Sciences on 6 of the 10 factors compared between the two stocks.

Get RUA Life Sciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for RUA and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RUA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

RUA vs. The Competition

Export
MetricRUA Life SciencesMedical Devices IndustryMedical SectorLON Exchange
Market Cap£11.02M£2.10B£7.05B£2.74B
Dividend Yield1.44%2.68%2.66%6.15%
P/E Ratio-2.6114.5926.13366.65
Price / Sales2.73124.04555.6686,088.64
Price / Cash2.4015.9929.0927.87
Price / Book0.854.4310.787.79
Net Income-£2.66M£144.75M£3.58B£5.89B
7 Day Performance-1.90%0.57%2.22%-0.58%
1 Month Performance-9.05%-1.39%-0.09%-1.02%
1 Year Performance44.80%-0.05%34.39%65.87%

RUA Life Sciences Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
RUA
RUA Life Sciences
N/AGBX 18.10
+2.0%		N/A+44.8%£11.02M£4.11MN/A48
IUG
Intelligent Ultrasound Group
N/AN/AN/AN/A£42.76M£6.57MN/A65
NCYT
Novacyt
N/AGBX 41.90
+27.0%		N/A-21.4%£30.35M£20.03MN/A120
IHC
Inspiration Healthcare Group
N/AGBX 22.49
0.0%		N/A-0.5%£20.17M£45.20MN/A224
AVO
Advanced Oncotherapy
N/AN/AN/AN/A£9.50MN/AN/A3,900

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:RUA) was last updated on 6/28/2026 by MarketBeat.com Staff.
From Our Partners
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Gold to $4,900—Here’s the Real Play
Gold is hitting new highs, fueled by tariffs and record central bank demand - 710 tonnes per quarter. JPMorgan...
Investors Alley | Sponsoredtc pixel
Porter flew 3,300 miles to investigate this system
Porter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...
Porter & Company | Sponsoredtc pixel
PH: Do THESE 4 things to your bank account now …
In a few short months, the US government could gain unprecedented powers over personal bank accounts - includi...
Weiss Ratings | Sponsoredtc pixel
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...
Profits Run | Sponsoredtc pixel
Do NOT Buy SpaceX – Do This Instead
SpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...
Stansberry Research | Sponsoredtc pixel